Impact of magnesium supplementation on clinical outcome and disease progression of patients with diabetic nephropathy: a prospective randomized trial
Halawa N, Elsaid TW, El Wakeel LM, Shawki MA
Therapeutic advances in chronic disease · 8 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-01-01 · Ther Adv Chronic Dis · vol. 14 · pág. 20406223231214641
- Editorial
- SAGE Publishing
- Citado
- 10 citas · más que el 77% de estudios similares · 1.2× el promedio de su campo
- Referencias
- 49 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Palabras clave
- Medicine, Internal medicine, Regimen, Glycemic, Creatinine, Renal function, Randomized controlled trial, Tolerability, Gastroenterology, Lipid profile, Urology, Endocrinology, Adverse effect, Insulin, Cholesterol
4 autores
- Nihal Halawa🇪🇬Ain Shams University
- Tamer Wahid Elsaid🇪🇬Ain Shams University
- Lamia Mohamed El Wakeel🇪🇬Ain Shams University
- May Ahmed Shawki🇪🇬 · autor de correspondenciaAin Shams University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Magnesium (Mg) deficiency is closely linked with proteinuria.
Objectives
To assess the impact of oral Mg citrate supplementation on the clinical outcome of diabetic nephropathy (DN) patients.
Design
This was a prospective, randomized, controlled, open-label study.
Methods
Sixty DN patients were recruited from Nephrology and Endocrinology departments, Ain Shams University Hospitals, Cairo, Egypt. Patients were assigned by stratified randomization based on their Mg status, to either Mg citrate group, (n = 30), who received the standard regimen + oral Mg citrate 2.25 g/day or Control group, (n = 30), who received the standard regimen only. The primary endpoint was a change in urinary albumin to creatinine ratio (UACR) after 12 weeks. Secondary outcomes were insulin resistance, glycemic control, lipid profile, serum osteocalcin, quality of life (QoL) and Mg tolerability.
Results
Out of a total of 60 patients enrolled, only 54 patients (26 in Mg citrate group and 28 in the control group) completed the study. Groups were comparable at baseline. The UACR median percent reduction was significantly higher in the Mg citrate group (-6.87%) versus (-0.9%) in the Control group, p = 0.001. After 12 weeks, the estimated glomerular filtration rate significantly improved in the Mg citrate group versus Control group (p = 0.001). Comparable change was observed in glycemic indices. Lipid profile significantly improved in the Mg citrate group versus Control group (p = 0.001). Serum osteocalcin levels significantly declined in the Mg citrate group (p = 0.001) versus control group. Regarding QoL, the total score and all domains significantly improved in the Mg citrate group compared to control. The Mg supplement was tolerable with only mild reported side effects that required no intervention.
Conclusion
Oral Mg citrate supplementation improved microalbuminuria in DN patients. It also had favorable effects on serum osteocalcin, lipid profile and QoL with no reported major side effects.
Trial registration
ClinicalTrials.gov identifier: NCT03824379.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.